Stryker Co. (NYSE:SYK) is Steigerwald Gordon & Koch Inc.’s 8th Largest Position

Steigerwald Gordon & Koch Inc. lessened its holdings in Stryker Co. (NYSE:SYK) by 1.3% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 68,349 shares of the medical technology company’s stock after selling 933 shares during the period. Stryker accounts for approximately 2.8% of Steigerwald Gordon & Koch Inc.’s holdings, making the stock its 8th biggest position. Steigerwald Gordon & Koch Inc.’s holdings in Stryker were worth $25,443,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of SYK. Capital & Planning LLC increased its stake in Stryker by 3.6% in the 4th quarter. Capital & Planning LLC now owns 841 shares of the medical technology company’s stock worth $304,000 after buying an additional 29 shares in the last quarter. Brighton Jones LLC increased its stake in Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock worth $1,643,000 after buying an additional 609 shares in the last quarter. U.S. Capital Wealth Advisors LLC increased its stake in Stryker by 1.4% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 3,572 shares of the medical technology company’s stock worth $1,286,000 after buying an additional 51 shares in the last quarter. Optas LLC increased its stake in Stryker by 9.1% in the 4th quarter. Optas LLC now owns 815 shares of the medical technology company’s stock worth $293,000 after buying an additional 68 shares in the last quarter. Finally, Trust Point Inc. increased its stake in Stryker by 7.7% in the 4th quarter. Trust Point Inc. now owns 1,885 shares of the medical technology company’s stock worth $679,000 after buying an additional 134 shares in the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Trading Up 0.5%

Shares of NYSE SYK opened at $382.87 on Thursday. The business’s 50 day moving average is $369.68 and its two-hundred day moving average is $376.11. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. Stryker Co. has a 1-year low of $314.93 and a 1-year high of $406.19. The stock has a market capitalization of $146.14 billion, a P/E ratio of 49.34, a PEG ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.73 by $0.11. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The business had revenue of $5.87 billion during the quarter, compared to analyst estimates of $5.68 billion. During the same quarter in the previous year, the business earned $2.50 earnings per share. The company’s revenue for the quarter was up 11.9% compared to the same quarter last year. As a group, research analysts expect that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Monday, June 30th will be given a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is presently 45.41%.

Wall Street Analyst Weigh In

Several brokerages have recently issued reports on SYK. Evercore ISI reduced their target price on Stryker from $400.00 to $390.00 and set an “outperform” rating on the stock in a report on Friday, May 2nd. Citigroup reaffirmed a “buy” rating and issued a $455.00 target price (up from $443.00) on shares of Stryker in a report on Thursday, May 22nd. The Goldman Sachs Group set a $422.00 target price on Stryker in a report on Tuesday, March 4th. Roth Mkm lifted their target price on Stryker from $405.00 to $456.00 and gave the stock a “buy” rating in a report on Friday, May 2nd. Finally, JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a report on Monday, May 5th. Five equities research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $427.30.

Insider Buying and Selling at Stryker

In related news, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the sale, the director now owns 3,417,326 shares in the company, valued at approximately $1,288,195,208.96. The trade was a 5.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 5.90% of the company’s stock.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.